Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $59,814 | 46 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Amgen Inc. | $52,995 | 42 | $0 (2022) |
| Daiichi Sankyo Inc. | $6,294 | 2 | $0 (2020) |
| UCB SA | $525.00 | 2 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $150.00 | 1 | UCB SA ($150.00) |
| 2022 | $3,060 | 4 | Amgen Inc. ($3,060) |
| 2021 | $1,905 | 5 | Amgen Inc. ($1,530) |
| 2020 | $8,184 | 6 | Daiichi Sankyo Inc. ($6,294) |
| 2019 | $4,275 | 7 | Amgen Inc. ($4,275) |
| 2018 | $16,215 | 11 | Amgen Inc. ($16,215) |
| 2017 | $26,025 | 12 | Amgen Inc. ($26,025) |
All Payment Transactions
46 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 08/31/2023 | UCB SA | — | Consulting Fee | Cash or cash equivalent | $150.00 | General |
| 05/16/2022 | Amgen Inc. | Prolia (Biological) | Consulting Fee | Cash or cash equivalent | $300.00 | General |
| Category: Bone Health | ||||||
| 04/27/2022 | Amgen Inc. | Prolia (Biological) | Consulting Fee | Cash or cash equivalent | $1,875.00 | General |
| Category: Bone Health | ||||||
| 03/09/2022 | Amgen Inc. | Prolia (Biological) | Consulting Fee | Cash or cash equivalent | $585.00 | General |
| Category: Bone Health | ||||||
| 02/24/2022 | Amgen Inc. | Prolia (Biological) | Consulting Fee | Cash or cash equivalent | $300.00 | General |
| Category: Bone Health | ||||||
| 12/02/2021 | Amgen Inc. | Prolia (Biological) | Consulting Fee | Cash or cash equivalent | $600.00 | General |
| Category: Bone Health | ||||||
| 05/17/2021 | Amgen Inc. | Prolia (Biological) | Consulting Fee | Cash or cash equivalent | $300.00 | General |
| Category: Bone Health | ||||||
| 04/13/2021 | Amgen Inc. | Prolia (Biological) | Consulting Fee | Cash or cash equivalent | $150.00 | General |
| Category: Bone Health | ||||||
| 03/19/2021 | Amgen Inc. | Prolia (Biological) | Consulting Fee | Cash or cash equivalent | $480.00 | General |
| Category: Bone Health | ||||||
| 01/04/2021 | UCB SA | — | Consulting Fee | Cash or cash equivalent | $375.00 | General |
| 09/08/2020 | Daiichi Sankyo Inc. | — | Consulting Fee | Cash or cash equivalent | $475.00 | General |
| 07/16/2020 | Daiichi Sankyo Inc. | — | Consulting Fee | Cash or cash equivalent | $5,818.75 | General |
| 04/20/2020 | Amgen Inc. | Prolia (Biological) | Consulting Fee | Cash or cash equivalent | $480.00 | General |
| Category: Bone Health | ||||||
| 02/27/2020 | Amgen Inc. | Prolia (Biological) | Consulting Fee | Cash or cash equivalent | $360.00 | General |
| Category: Bone Health | ||||||
| 02/19/2020 | Amgen Inc. | XGEVA (Biological) | Consulting Fee | Cash or cash equivalent | $360.00 | General |
| Category: Oncology | ||||||
| 01/21/2020 | Amgen Inc. | XGEVA (Biological) | Consulting Fee | Cash or cash equivalent | $690.00 | General |
| Category: Oncology | ||||||
| 11/15/2019 | Amgen Inc. | XGEVA (Biological) | Consulting Fee | Cash or cash equivalent | $150.00 | General |
| Category: Oncology | ||||||
| 10/09/2019 | Amgen Inc. | XGEVA (Biological) | Consulting Fee | Cash or cash equivalent | $150.00 | General |
| Category: Oncology | ||||||
| 06/24/2019 | Amgen Inc. | XGEVA (Biological) | Consulting Fee | Cash or cash equivalent | $1,125.00 | General |
| Category: Oncology | ||||||
| 04/10/2019 | Amgen Inc. | XGEVA (Biological) | Consulting Fee | Cash or cash equivalent | $225.00 | General |
| Category: Oncology | ||||||
| 03/14/2019 | Amgen Inc. | XGEVA (Biological) | Consulting Fee | Cash or cash equivalent | $1,425.00 | General |
| Category: Oncology | ||||||
| 02/04/2019 | Amgen Inc. | XGEVA (Biological) | Consulting Fee | Cash or cash equivalent | $825.00 | General |
| Category: Oncology | ||||||
| 02/04/2019 | Amgen Inc. | XGEVA (Biological) | Consulting Fee | Cash or cash equivalent | $375.00 | General |
| Category: Oncology | ||||||
| 11/06/2018 | Amgen Inc. | XGEVA (Biological) | Consulting Fee | Cash or cash equivalent | $450.00 | General |
| Category: Oncology | ||||||
| 09/19/2018 | Amgen Inc. | XGEVA (Biological) | Consulting Fee | Cash or cash equivalent | $450.00 | General |
| Category: Oncology | ||||||
About Mark Schubert, DDS, MSD
Mark Schubert, DDS, MSD is a Dentist healthcare provider based in Seattle, Washington. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/12/2006. The National Provider Identifier (NPI) number assigned to this provider is 1245329416.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Mark Schubert, DDS, MSD has received a total of $59,814 in payments from pharmaceutical and medical device companies, with $150.00 received in 2023. These payments were reported across 46 transactions from 3 companies. The most common payment nature is "Consulting Fee" ($59,814).
Practice Information
- Specialty Dentist
- Location Seattle, WA
- Active Since 10/12/2006
- Last Updated 10/18/2007
- Taxonomy Code 122300000X
- Entity Type Individual
- NPI Number 1245329416
Products in Payments
- XGEVA (Biological) $47,565
- Prolia (Biological) $5,430
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Dentist Doctors in Seattle
John Sorensen
Dentist — Payments: $181,612
Dr. Matthew Epstein, Dds, DDS
Dentist — Payments: $11,106
Alireza Sadr, Dds Phd, DDS PHD
Dentist — Payments: $9,414
Dr. Rebecca Bockow, Dds, DDS
Dentist — Payments: $8,038
Dr. Lina Kim, Dds, DDS
Dentist — Payments: $7,941
Aaron Wong, Dds, DDS
Dentist — Payments: $6,950